EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

Orally dissolving pilocarpine tablets for xerostomia in advanced cancer: A pilot N-of-1 feasibility study

Karyn Foster iD, Geoff Mitchell, Evan Richard, Kathryn J Steadman, Hugh Senior, Rose Estafanos, Janet Hardy iD

Palliative Medicine · 2025-02 · 39 (2) · 298-306

DOI: 10.1177/02692163241306269 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Palliative Medicine, online erschienen am 24.12.2024. Verfasst von Karyn Foster und 6 weiteren Autor:innen. Beteiligte Einrichtung: Palliative and Supportive Care, Mater Misericordiae Ltd., South Brisbane, QLD, Australia. Hauptthemen laut MEDLINE: Pilocarpine, Xerostomia, Neoplasms, Muscarinic Agonists. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 34 Literaturangaben. Gefördert von: Mater Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Xerostomia is a common and difficult symptom experienced by patients with cancer. Pilocarpine is a cholinergic agent that stimulates salivation.

Aim

To assess the feasibility of conducting a N-of-1 trial to determine the efficacy of pilocarpine orally dissolving tablets in patients with xerostomia.

Design

Double-blind, crossover, placebo-controlled N-of-1 trials of 5 mg pilocarpine tablets vs placebo. Each trial consisted of three 6-day cycles containing pilocarpine (3 days) and placebo (3 days) in random order. Setting/participants: Participants with advanced cancer and xerostomia (scoring >3 on an 11-point numerical rating scale) from any cause, were recruited from an inpatient and outpatient palliative care unit in Brisbane, Australia.

Results

Eighteen people were recruited in 17 months. Nine withdrew, seven before or during the first 4 days. Three withdrew due to unacceptable side effects. Two participants met the definition of response (⩾2 point reduction in mean scores active vs placebo cycles). When assessing individual cycles, 15 out of 27 cycles (56%) met the definition of response. More people reported at least one mild episode during pilocarpine than placebo of nausea (6 vs 3), vomiting (3 vs 0) and sweating (3 vs 2). About 48% of adverse event classifications were reported in placebo cycles only.

Conclusion

Recruitment to an N-of-1 trial for xerostomia is feasible but attrition was high (50%). Early dropout may have been due to the trial length, complexity, appropriateness or number of questionnaires. Adverse events were generally mild. Two of 10 participants were considered to have benefited from pilocarpine warranting ongoing treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PilocarpineXerostomiaNeoplasmsMuscarinic AgonistsHumansMaleFemaleDouble-Blind MethodFeasibility StudiesPilot ProjectsCross-Over StudiesMiddle AgedAgedAdministration, OralTabletsAged, 80 and overAdultAustralia

Stichwörter der Autor:innen

Pilocarpinecancercross-over studiesdry mouthfeasibility studiespalliative caresingle-subject trialxerostomia

Substanzen

PilocarpineTabletsMuscarinic Agonists

Autor:innen und Institutionen

  • Palliative and Supportive Care, Mater Misericordiae Ltd., South Brisbane, QLD, Australia.
  • Palliative and Supportive Care Research, Mater Research Institute, University of Queensland, South Brisbane, QLD, Australia.
  • General Practice and Palliative Care, University of Queensland, Brisbane, QLD, Australia.
  • School of Pharmacy, University of Queensland, Brisbane, QLD, Australia.
  • School of Health Sciences, College of Health Massey University, Auckland, New Zealand.

ORCID-Profile: Karyn Foster, Janet Hardy

Förderung

  • Mater Foundation

Zitieren

APA

Foster, K., Mitchell, G., Richard, E., Steadman, K. J., Senior, H., Estafanos, R., & Hardy, J. (2025). Orally dissolving pilocarpine tablets for xerostomia in advanced cancer: A pilot N-of-1 feasibility study. Palliative Medicine, 39(2), 298-306. https://doi.org/10.1177/02692163241306269

Vancouver

Foster K, Mitchell G, Richard E, Steadman KJ, Senior H, Estafanos R, et al. Orally dissolving pilocarpine tablets for xerostomia in advanced cancer: A pilot N-of-1 feasibility study. Palliative Medicine. 2025;39(2):298-306. doi:10.1177/02692163241306269

BibTeX
@article{Foster2025,
  author = {Foster, Karyn and Mitchell, Geoff and Richard, Evan and Steadman, Kathryn J and Senior, Hugh and Estafanos, Rose and Hardy, Janet},
  title = {Orally dissolving pilocarpine tablets for xerostomia in advanced cancer: A pilot N-of-1 feasibility study},
  journal = {Palliative Medicine},
  year = {2025},
  volume = {39},
  number = {2},
  pages = {298--306},
  doi = {10.1177/02692163241306269}
}
Kostenlos starten →